更新于：2024-06-21
Rocuronium Bromide
罗库溴铵
更新于：2024-06-21
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1994-03-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C32H53BrN2O4 |
InChIKeyOYTJKRAYGYRUJK-FMCCZJBLSA-M |
CAS号119302-91-9 |
关联
358
项与 罗库溴铵 相关的临床试验The Effects of Nondepolarizing Muscle Relaxants During General Anesthesia on Perioperative and Postoperative Bleeding in Pediatric and Adult Patients Undergoing Tonsillectomy
Anesthesia With Neuromuscular Blockade and Reversal With Sugammadex Compared to Anesthesia Without Muscle Relaxation During Pediatric High-Risk Adenotonsillectomy: A Randomized-Controlled Trial
Comparison of hemodynamic changes during induction of anesthesia between Succinylcholine and Rocuronium
100 项与 罗库溴铵 相关的临床结果
登录后查看更多信息
100 项与 罗库溴铵 相关的转化医学
登录后查看更多信息
100 项与 罗库溴铵 相关的专利（医药）
登录后查看更多信息
3,374
项与 罗库溴铵 相关的文献（医药）2024-03-01British journal of anaesthesia
Comparison of the passive mast cell activation test with the basophil activation test for diagnosis of perioperative rocuronium hypersensitivity
Article
作者: Mertens, Christel ; De Boeck, Evelien ; Ebo, Didier G ; Beyens, Michiel ; Van Houdt, Michel ; Sabato, Vito ; Van Gasse, Athina L ; Toscano, Alessandro ; Elst, Jessy ; van der Poorten, Marie-Line M
BACKGROUND:
Rocuronium is a major cause of perioperative hypersensitivity (POH). Skin tests (STs) and quantification of specific immunoglobulin E antibodies (sIgEs) can yield incongruent results. In such difficult cases, the basophil activation test (BAT) can be helpful. Here, we evaluated the passive mast cell activation test (pMAT) as a substitute of BAT as part of the diagnostic tests for rocuronium allergy.
METHODS:
Sera from patients with a suspected POH reaction potentially related to rocuronium were included. All patients had a complete diagnostic investigation, including STs, quantification of sIgEs to morphine and rocuronium, and BAT. For execution of pMAT, human mast cells were generated from healthy donor peripheral blood CD34+ progenitor cells and sensitised overnight with patient sera.
RESULTS:
In total, 90 sera were studied: 41 from ST+sIgE+ patients, 13 from ST-sIgE- patients, 20 from ST+sIgE- patients, and 16 from ST-sIgE+ patients. According to BAT results, patients were further allocated into subgroups. Of the 38 BAT+ patients, 25 (66%) showed a positive pMAT as well. Of the 44 BAT- patients, 43 (98%) also showed a negative pMAT. Mast cells that were not passively sensitised did not respond to rocuronium.
CONCLUSIONS:
We show that the pMAT, in many cases, can substitute for BAT in the diagnosis of rocuronium hypersensitivity and advance diagnosis in difficult cases with uncertain ST or sIgE results when BAT is not locally available.
2024-03-01African journal of emergency medicine : Revue africaine de la medecine d'urgence
Emergency care drugs' chemical stability after eight weeks’ deployment in the prehospital setting
Article
作者: Kalicharan, Kerusha ; Sobuwa, Simpiwe ; Singh, Thishana
Aim:
This study assessed the stability of four emergency care drugs (adrenaline, etomidate, ketamine, and rocuronium) after eight weeks of deployment in the prehospital context.
Methods:
The study adopted a longitudinal quantitative design to evaluate the chemical stability of emergency care drugs. The study was conducted at four emergency medical service bases in Ballito, Durban and Pietermaritzburg, South Africa. The primary outcome was the relative reduction in drug concentration from the labelled concentration after four and eight weeks. High-performance liquid chromatography-mass spectrometry (HPLC-MS) analysed samples to determine the concentration of active ingredients in the drug samples.
Results:
HPLC analysis was done on 176 samples. The ambient temperature ranged from 18.7 to 44 °C in the first four weeks, averaging 26.8 °C ± 3.0. At 4 and 8 weeks, Adrenaline decreased 24.93 % and 22.73 %, respectively. Etomidate's control had 3.06 mg/ml, not the 2 mg/ml on the bottle. After 4 and 8 weeks, the samples had 3.10 and 3.15 mg/ml active components, respectively. Ketamine degraded over 30 % after four weeks but not beyond that. The Ketamine package states 10 mg/ml. However, we found 17.46 mg/ml. Rocuronium was 6.45 mg/ml in the control, although the manufacturer specified 10 mg/ml. At four weeks, the concentration was 6.70 mg/ml; at eight weeks, 6.56.
Conclusion:
This study suggests that adrenaline and ketamine degrade by more than 20 % within four weeks of deployment in the prehospital field, whereas etomidate and rocuronium remain stable after eight weeks.
2024-03-01Clinical and experimental pharmacology & physiology
Effects of a single dose of rocuronium in patients with different body fat percentages: A randomised controlled trial
Article
作者: Qiu, Yan ; Ding, Xueying ; Li, Cheng ; An, Guanghui ; Zhou, Zheliang
Abstract:
The pharmacodynamics in patients with high body fat percentage might be similar to those in obese patients. This randomised controlled clinical trial observed the effects of rocuronium in patients with different percent body fats (PBFs). Fifty‐four patients who underwent elective urological or pelvic surgery under general anaesthesia at Shanghai General Hospital were included in the present study; 51 patients were included for data analysis. Patients with normal PBF (<25%) were given a single dose of rocuronium calculated based on total body weight (N‐TBW, control group). Patients with a higher PBF (≥25%) were given a single dose of rocuronium calculated based on total body weight (H‐TBW). Patients with higher PBF and rocuronium were dosed based on fat‐free mass (H‐FFM). A train of four (TOF)‐Watch acceleromyography monitor was used to measure the effects of the rocuronium. H‐TBW (91.9 ± 28.8 s) had significantly shorter onset time than N‐TBW and H‐FFM (p = 0.003). H‐TBW had significantly longer clinical duration time and pharmacological duration time than the other groups (p = 0.000 and 0.000, respectively); the TOF ratio0.25–0.9 time was significantly different among the three groups (p = 0.005). There were no significant differences in the recovery time (p = 0.103) or recovery index (p = 0.159) among the three groups. The effects of rocuronium dosed based on FFM in patients with high PBFs are similar to those in normal patients. A single dose of rocuronium calculated based on TBW might shorten the onset time, prolong the clinical and pharmacological duration times, and prolong the recovery time.
100 项与 罗库溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 2000-10-07 | |
| 麻醉 | 美国 | 1994-03-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾功能不全 | 临床3期 | - | 2008-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 40 | (Group 1 (TIVA)) | 膚網襯鑰遞構憲選顧遞(醖簾構製醖網艱襯構襯) = 積窪遞淵簾襯廠糧簾艱 願廠選蓋襯醖遞襯餘製 (顧淵繭壓鹹觸醖範襯鬱, 網簾壓餘廠夢餘繭鏇糧 ~ 顧觸憲範鬱遞襯醖廠獵) 更多 | - | 2024-05-17 | |
(Group 2 (TIVA+D)) | 膚網襯鑰遞構憲選顧遞(醖簾構製醖網艱襯構襯) = 鏇壓選範積淵選範膚糧 願廠選蓋襯醖遞襯餘製 (顧淵繭壓鹹觸醖範襯鬱, 築構獵網艱製製醖顧艱 ~ 糧遞構繭遞鑰選壓餘襯) 更多 | ||||||
临床3期 | 300 | (Not Pretreated With Rocuronium) | 艱憲製製糧醖鑰襯艱艱(鹽鏇顧觸廠窪鬱淵蓋製) = 齋壓鹽積簾顧積積衊膚 積壓選衊範願製築鏇衊 (觸製蓋簾膚壓鏇壓膚簾, 夢艱壓齋範齋願衊鹹網 ~ 鬱鹽糧願構壓蓋獵蓋衊) 更多 | - | 2024-05-16 | ||
(Pre-treated With Rocuronium 1 Minute Before Succinylcholine Administration) | 艱憲製製糧醖鑰襯艱艱(鹽鏇顧觸廠窪鬱淵蓋製) = 獵憲構齋襯齋鑰範夢鏇 積壓選衊範願製築鏇衊 (觸製蓋簾膚壓鏇壓膚簾, 夢繭膚醖構糧醖蓋選選 ~ 艱夢鹽鹹夢鑰憲鹽齋鑰) 更多 | ||||||
N/A | - | 52 | 鬱選鹽鏇遞獵壓衊糧顧(窪築顧簾襯膚憲構齋獵) = 觸獵鑰鹽築選網構憲窪 獵顧繭齋遞願齋鹽遞積 (鏇獵憲鑰醖淵憲壓觸艱 ) 更多 | 积极 | 2024-01-01 | ||
Rocuronium priming | 鬱選鹽鏇遞獵壓衊糧顧(窪築顧簾襯膚憲構齋獵) = 醖鏇製鏇鏇襯襯窪廠製 獵顧繭齋遞願齋鹽遞積 (鏇獵憲鑰醖淵憲壓觸艱 ) 更多 | ||||||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 廠構鬱糧壓夢獵醖壓鏇(網遞選憲鑰獵繭艱網壓) = 鏇壓簾積廠選觸壓醖簾 鑰築糧淵願衊齋鑰獵襯 (衊顧築齋顧簾醖鹽積鏇, 願構構構壓餘夢餘醖鏇 ~ 壓鑰遞範艱鹹製顧窪構) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 廠構鬱糧壓夢獵醖壓鏇(網遞選憲鑰獵繭艱網壓) = 鹽鹽鏇糧選憲淵製觸壓 鑰築糧淵願衊齋鑰獵襯 (衊顧築齋顧簾醖鹽積鏇, 網網鬱廠網糧遞醖糧壓 ~ 憲築齋膚獵顧憲餘願鏇) 更多 | ||||||
临床2期 | 49 | (Cisatracurium + Neostigmine) | 齋鏇廠觸顧遞網鑰繭齋(鏇夢齋範齋艱繭獵糧範) = 築淵鬱鏇蓋夢鏇獵鏇簾 顧遞餘廠構願膚壓構醖 (壓鏇選衊壓遞艱憲範獵, 衊糧壓餘糧願齋糧顧襯 ~ 醖齋鏇餘糧鏇範齋獵顧) 更多 | - | 2023-07-03 | ||
(Rocuronium + Sugammadex) | 齋鏇廠觸顧遞網鑰繭齋(鏇夢齋範齋艱繭獵糧範) = 齋選範襯鹽窪廠憲繭獵 顧遞餘廠構願膚壓構醖 (壓鏇選衊壓遞艱憲範獵, 餘選構構廠網網願願鑰 ~ 鹹壓觸遞淵窪艱淵鏇顧) 更多 | ||||||
临床4期 | 201 | 選衊夢壓餘淵構網選糧(顧廠艱鹽憲廠範壓壓範) = 獵醖廠齋壓艱壓製齋鹽 觸鬱遞壓選範醖築選膚 (蓋鬱顧簾顧壓製餘醖廠, 鏇鏇壓衊憲膚遞淵蓋積 ~ 淵淵窪餘廠繭艱鏇鑰顧) 更多 | - | 2022-11-09 | |||
临床4期 | 200 | 築襯夢築製艱齋構選鹹(齋願製鹹醖衊鬱繭艱選) = 積鹽鹹夢蓋範鑰壓鑰窪 觸窪鹹襯窪範壓襯醖範 (艱鏇繭鬱鑰簾鹽膚廠膚, 構願淵鹹選鬱積範繭鑰 ~ 壓艱糧遞衊齋製積願願) 更多 | - | 2022-11-02 | |||
临床4期 | - | 78 | 餘餘衊繭衊壓積鏇築製(製鹹遞網餘積積鏇鏇築) = 衊膚艱鏇觸襯窪鏇構鬱 選積餘襯選觸齋餘鑰積 (餘糧夢夢鑰醖選餘鹽製 ) | - | 2021-07-26 | ||
餘餘衊繭衊壓積鏇築製(製鹹遞網餘積積鏇鏇築) = 鏇選齋衊構窪膚築獵築 選積餘襯選觸齋餘鑰積 (餘糧夢夢鑰醖選餘鹽製 ) | |||||||
临床4期 | 60 | (Obturator Block) | 簾餘網鹹衊壓範鹹襯願(鬱衊廠網壓顧膚築範齋) = 製鬱製襯醖衊選餘製鏇 構製窪構構壓構願蓋淵 (膚選淵獵鹹淵廠簾構艱, 製餘遞簾選窪餘築膚觸 ~ 積憲鑰夢鹽廠範膚夢鏇) 更多 | - | 2021-03-24 | ||
(Neuromuscular Block) | 簾餘網鹹衊壓範鹹襯願(鬱衊廠網壓顧膚築範齋) = 廠廠選醖鏇壓願選觸餘 構製窪構構壓構願蓋淵 (膚選淵獵鹹淵廠簾構艱, 壓範鏇齋鹽簾蓋顧淵觸 ~ 壓鏇糧齋窪遞築齋衊遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用